Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Retracted: The Copper Radioisotopes: A Systematic Review with Special Interest to .

BioMed research international

BioMed Research International.
PMID: 30069467
Biomed Res Int. 2018 Jul 08;2018:3860745. doi: 10.1155/2018/3860745. eCollection 2018.

[This retracts the article DOI: 10.1155/2014/786463.].

Cite
BioMed Research International. Retracted: The Copper Radioisotopes: A Systematic Review with Special Interest to . Biomed Res Int. 2018;2018:3860745doi: 10.1155/2018/3860745.
BioMed Research International. (2018). Retracted: The Copper Radioisotopes: A Systematic Review with Special Interest to . BioMed research international, 20183860745. https://doi.org/10.1155/2018/3860745
BioMed Research International. "Retracted: The Copper Radioisotopes: A Systematic Review with Special Interest to ." BioMed research international vol. 2018 (2018): 3860745. doi: https://doi.org/10.1155/2018/3860745
BioMed Research International. Retracted: The Copper Radioisotopes: A Systematic Review with Special Interest to . Biomed Res Int. 2018 Jul 08;2018:3860745. doi: 10.1155/2018/3860745. eCollection 2018. PMID: 30069467; PMCID: PMC6057420.
Copy Download .nbib Format: NLM
Development of a two-antibody model for the evaluation of copper-64 radioimmunotherapy.

Veterinary and comparative oncology

Bryan JN, Lewis MR, Henry CJ, Owen NK, Zhang J, Mohsin H, Jia F, Sivaguru G, Anderson CJ.
PMID: 19379188
Vet Comp Oncol. 2004 Jun;2(2):82-90. doi: 10.1111/j.1476-5810.2004.00041.x.

Copper-64 emits beta(+) and beta(-) particles suitable for positron emission tomography and radioimmunotherapy (RIT) of cancer. Copper-64-labelled antibodies have caused complete responses in laboratory animal RIT studies at far lower radiation doses than traditionally prescribed. The intracellular localization of...

Cite
Bryan JN, Lewis MR, Henry CJ, et al. Development of a two-antibody model for the evaluation of copper-64 radioimmunotherapy. Vet Comp Oncol. 2004;2(2):82-90doi: 10.1111/j.1476-5810.2004.00041.x.
Bryan, J. N., Lewis, M. R., Henry, C. J., Owen, N. K., Zhang, J., Mohsin, H., Jia, F., Sivaguru, G., & Anderson, C. J. (2004). Development of a two-antibody model for the evaluation of copper-64 radioimmunotherapy. Veterinary and comparative oncology, 2(2), 82-90. https://doi.org/10.1111/j.1476-5810.2004.00041.x
Bryan, J N, et al. "Development of a two-antibody model for the evaluation of copper-64 radioimmunotherapy." Veterinary and comparative oncology vol. 2,2 (2004): 82-90. doi: https://doi.org/10.1111/j.1476-5810.2004.00041.x
Bryan JN, Lewis MR, Henry CJ, Owen NK, Zhang J, Mohsin H, Jia F, Sivaguru G, Anderson CJ. Development of a two-antibody model for the evaluation of copper-64 radioimmunotherapy. Vet Comp Oncol. 2004 Jun;2(2):82-90. doi: 10.1111/j.1476-5810.2004.00041.x. PMID: 19379188.
Copy Download .nbib Format: NLM
Cross-Bridged Cyclam with Phosphonate and Phosphinate Pendant Arms: Chelators for Copper Radioisotopes with Fast Complexation.

Inorganic chemistry

Pazderová L, David T, Hlinová V, Plutnar J, Kotek J, Lubal P, Kubíček V, Hermann P.
PMID: 32437603
Inorg Chem. 2020 Jun 15;59(12):8432-8443. doi: 10.1021/acs.inorgchem.0c00856. Epub 2020 May 21.

Cross-bridged cyclam derivatives bearing two phosphonate (H

Cite
Pazderová L, David T, Hlinová V, et al. Cross-Bridged Cyclam with Phosphonate and Phosphinate Pendant Arms: Chelators for Copper Radioisotopes with Fast Complexation. Inorg Chem. 2020;59(12):8432-8443doi: 10.1021/acs.inorgchem.0c00856.
Pazderová, L., David, T., Hlinová, V., Plutnar, J., Kotek, J., Lubal, P., Kubíček, V., & Hermann, P. (2020). Cross-Bridged Cyclam with Phosphonate and Phosphinate Pendant Arms: Chelators for Copper Radioisotopes with Fast Complexation. Inorganic chemistry, 59(12), 8432-8443. https://doi.org/10.1021/acs.inorgchem.0c00856
Pazderová, Lucia, et al. "Cross-Bridged Cyclam with Phosphonate and Phosphinate Pendant Arms: Chelators for Copper Radioisotopes with Fast Complexation." Inorganic chemistry vol. 59,12 (2020): 8432-8443. doi: https://doi.org/10.1021/acs.inorgchem.0c00856
Pazderová L, David T, Hlinová V, Plutnar J, Kotek J, Lubal P, Kubíček V, Hermann P. Cross-Bridged Cyclam with Phosphonate and Phosphinate Pendant Arms: Chelators for Copper Radioisotopes with Fast Complexation. Inorg Chem. 2020 Jun 15;59(12):8432-8443. doi: 10.1021/acs.inorgchem.0c00856. Epub 2020 May 21. PMID: 32437603.
Copy Download .nbib Format: NLM
Somatostatin analogues labeled with copper radioisotopes: current status.

Journal of radioanalytical and nuclear chemistry

Marciniak A, Brasuń J.
PMID: 28804185
J Radioanal Nucl Chem. 2017;313(2):279-289. doi: 10.1007/s10967-017-5323-x. Epub 2017 Jun 13.

Peptide receptor radionuclide therapy (PRRT) is a promising way to treat patients with inoperable tumors or metastatic neuroendocrine tumors. This therapeutic strategy is using radiolabeled peptides, which are capable of selective biding to receptors overexpressed in the cancer cells....

Cite
Marciniak A, Brasuń J. Somatostatin analogues labeled with copper radioisotopes: current status. J Radioanal Nucl Chem. 2017;313(2):279-289doi: 10.1007/s10967-017-5323-x.
Marciniak, A., & Brasuń, J. (2017). Somatostatin analogues labeled with copper radioisotopes: current status. Journal of radioanalytical and nuclear chemistry, 313(2), 279-289. https://doi.org/10.1007/s10967-017-5323-x
Marciniak, Aleksandra, and Brasuń, Justyna. "Somatostatin analogues labeled with copper radioisotopes: current status." Journal of radioanalytical and nuclear chemistry vol. 313,2 (2017): 279-289. doi: https://doi.org/10.1007/s10967-017-5323-x
Marciniak A, Brasuń J. Somatostatin analogues labeled with copper radioisotopes: current status. J Radioanal Nucl Chem. 2017;313(2):279-289. doi: 10.1007/s10967-017-5323-x. Epub 2017 Jun 13. PMID: 28804185; PMCID: PMC5533839.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries